1. Healthcare

  2. •

    Biotechnology
Foundation Medicine, Inc.

Foundation Medicine, Inc.

FMI
Foundation Medicine, Inc.US flagNASDAQ
137.00
USD
- -
- -
Foundation Medicine, Inc.
FMI
(NASDAQ)

Recent

price

137.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
TTM
FRC
1.67
0.77
3.12
2.18
2.84
3.36
4.26
5.51
Revenue per Share
-14.06
-1.63
-4.64
-1.87
-2.73
-3.25
-4.5
-3.87
Basic EPS, GAAP
-15.85
-1.47
-4.06
-1.88
-2.72
-2.53
-3.81
-3.72
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-19.82
-3.37
-9.66
-5.08
-7.05
-9.91
-14.11
-15.28
Book Value per Share
-18.09
-3.12
14.17
3.08
7.85
4.74
0.88
-0.23
Tangible Book Value per Share
1
14
9
28
33
35
36
37
Basic Weighted Avg Shares
2
11
29
61
93
117
153
201
Sales/Revenue/Turnover
-766.7
-205.83
-144.05
-87.24
-96.3
-97.39
-105.26
-68.74
Operating Margin (%)
2
3
5
8
11
16
19
20
Depreciation Expense
-17
-22
-43
-52
-90
-113
-161
-142
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-828.25
-210.36
-148.13
-85.5
-96.17
-96.86
-105.6
-70.28
Profit Margin (%)
8
50
118
73
200
128
57
55
Working Capital
3
1
- -
- -
- -
- -
60
110
LT Debt
-22
-43
132
86
258
165
32
-9
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'17
Mar'18
Jun'18
ST Debt
- -
- -
- -
LT Borrowings
60
90
110
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
37
37
37
Market Capitalization
2,447
2,852
4,999

Working Capital

FRC

•

in mil. unless spec.
Dec'17
Mar'18
Jun'18
Total Current Assets
124
131
137
Cash, Cash Equivalents & STI
71
60
53
Accounts Receivable, Net
30
32
41
Inventories
13
16
26
Total Current Liabilities
66
58
82
Payables & Accruals
59
48
61
ST Debt
- -
- -
- -
Deferred Revenue
6
8
19

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-71.17%
-80.79%
Free Cash Flow
- -
49.52%
55.2%
Net Income, GAAP
- -
50.79%
42.65%
Sales/Revenue/Turnover
- -
78.37%
30.84%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
30
28
29
29
117
2017
26
35
43
49
153
2018
53
57
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
-0.5
-0.84
-0.9
-1.02
-3.25
2017
-1.31
-1.24
-0.9
-1.05
-4.5
2018
-1.02
-0.9
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -
Similar Companies
Pharma Mar, S.A. (0RC6.IL)
Atara Biotherapeutics, Inc. (ATRA)
ReNerve Limited (RNV.AX)
Steminent Biotherapeutics Inc. (7729.TWO)
Mymetics Corporation (MYMX)
Delta-Fly Pharma, Inc. (4598.T)
Business
Foundation Medicine, Inc. (FMI) develops, manufactures and sells comprehensive genomic profiling tests based on next-generation sequencing technology for solid tumors, hematologic malignancies and sarcomas to inform precision oncology treatment decisions. The company's core products include FoundationOne CDx, a tissue-based companion diagnostic assay approved for multiple tumor types such as ovarian, lung, breast, colorectal and melanoma cancers; FoundationOne Liquid CDx, a blood-based liquid biopsy test analyzing over 300 cancer-related genes; FoundationOne Heme for hematologic malignancies; and FoundationCore, a database of more than 300,000 anonymized genomic profiles across over 150 cancer subtypes. It also offers molecular insights platforms and biopharma services to support clinical trials and drug development. FMI, founded in 2010 and headquartered in Boston, Massachusetts, operates as an independent affiliate of Roche following the Swiss company's complete $2.4 billion acquisition of the remaining shares in 2018, with additional locations across North America and Germany. Recent developments include achieving a historic milestone of 100 approved and actionable companion diagnostics in December 2025; expanding partnerships such as with Sequanta for technology transfers of FoundationOne Liquid CDx in 2023 and CDx in 2024, Massive Bio to enhance clinical trial access, and Manifold to integrate AI analytics into FoundationInsights; and awarding grants to address disparities in biomarker testing for breast and prostate cancers.

Company News

Company News APIChatGPT

  • gurufocus.com

    Is Fastenal Co (FAST) Overvalued After Q3 Earnings Beat? EPS at $0.35 vs Estimated $0.34, Revenue at $2.463 Billion vs Estimated $2.440 Billion -- GF Score: 95/100

  • gurufocus.com

    Fastenal Co (FAST) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amid Pricing Challenges

  • prnewswire.com

    Spirit Announces Sale of Fiber Materials Inc. (FMI) to Tex Tech Industries

  • prnewswire.com

    Spirit Announces Purchase Agreement with Tex Tech Industries for Intended Sale of Fiber Materials, Inc. (FMI)

  • globenewswire.com

    Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator